Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET
Company Participants
Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communications
Fred Vogt - Interim President & Chief Executive Officer
Jim Ziegler - Executive Vice President, Commercial
Igor Bilinsky - Chief Operating Officer
Friedrich Finckenstein - Chief Medical Officer
Jean-Marc Bellemin - Chief Financial Officer
Raj Puri - Executive Vice President, Regulatory Strategy & Translational Medicine
Conference Call Participants
Yanan Zhu - Wells Fargo
Tyler Van Buren - TD Cowen
Peter Lawson - Barclays
Colleen Kusy - Baird
Dina Elmonshed - Jefferies
Joseph Catanzaro - Piper Stanley
Asthika Goonewardene - Truist Securities
Reni Benjamin - Citizens JMP
Andrea Tan - Goldman Sachs
Kelsey Goodwin - Guggenheim
Ben Burnett - Stifel
Operator
Welcome to the Iovance Biotherapeutics Conference Call to discuss the Full Year 2023 Results and recent Corporate Updates. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.
I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sarah, you may begin.
Sara Pellegrino
Thank you, operator. Good afternoon and thank you for joining our conference call and webcast to discuss full year 2023 results and recent corporate update.
Dr. Fred Vogt, our Interim President and Chief Executive Officer; will provide a brief introduction. Jim Ziegler, EVP Commercial, will highlight our initial insights for the U.S. commercial launch of AMTAGVI, following the recent U.S. Food and Drug Administration or FDA approval in advanced melanoma.
Igor Bilinsky, Chief Operating Officer, will highlight commercial manufacturing and capacity expansion plans. Friedrich Finckenstein, our Chief Medical Officer, will summarize key clinical pipeline highlights; and Jean-Marc Bellemin, Chief Financial Officer will review our financial results.
Dr. Brian Gastman, EVP, Medical Affairs; and Raj Puri, EVP, Regulatory Strategy and Translational Medicine are also on the call and available for the Q&A session.
Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue, commercial activities, clinical trials and results, regulatory approvals and interactions, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interactions, licenses and collaboration, cash position and expense guidance, and future updates.